You Position: Home > Paper

Target therapy of non-small cell lung cancer directed by biomarkers

( views:543, downloads:388 )
Author:
No author available
Journal Title:
CANCER RESEARCH AND CLINIC
Issue:
9
DOI:
10.3760/cma.j.issn.1006-9801.2010.09.004
Key Word:
癌,非小细胞肺;靶向治疗;生物学标志;Carcinoma,non-small-cell lung;Target therapy;Biological markers

Abstract: Lung cancer is one of the most frequent malignant tumors. Target therapy is a milestone of non-small cell lung cancer (NSCLC) treatment in the 21st century. Biomarker detections have provided a solid foundation for individualized treatment. This review mainly focused on significance of EGFR mutation detection in EGFR tyrosine kinase inhibitors (EGFR-TKIs) as first line, second line and maintenance therapy in NSCLC. Simultaneously, this review introduced predicting significance of EGFR FISH test for the response of TKI treatment, and analyzed potential predictive biomarkers for antiangiogenic agents and status of antiEGFR monoclonal antibody in NSCLC individual therapy.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn